{
  "note_id": "gold_t2dm_005",
  "scenario": "t2dm",
  "persona": "gold",
  "note_text": "**Clinical Note**\n\n**Patient Name:** Jane Doe  \n**Date of Birth:** [DOB]  \n**Date of Visit:** [Date]  \n**Age:** 35 years  \n**Gender:** Female  \n**Occupation:** Elementary Teacher\n\n**Chief Complaint:**  \nDiabetes follow-up\n\n**History of Present Illness:**  \nJane Doe is a 35-year-old female with a 3-year history of Type 2 Diabetes Mellitus, presenting for routine management. Her last HbA1c, taken 3 months ago, was 8.2%. She reports fasting glucose readings between 160-220 mg/dL and postprandial readings from 180-250 mg/dL. She is currently on Metformin 1000mg twice daily and reports occasional gastrointestinal upset but generally tolerates it well. She denies any episodes of hypoglycemia. She has not experienced polyuria, polydipsia, or weight loss but reports occasional tingling in her feet. She had a dilated eye exam 8 months ago, which showed no retinopathy. Her lifestyle includes a sedentary job, minimal exercise, and daily soda consumption. She struggles with portion control.\n\n**Review of Systems:**  \n- **General:** No recent weight loss, no fatigue.  \n- **Neurological:** Reports tingling in feet, no headaches, no dizziness.  \n- **Endocrinological:** No polyuria, no polydipsia.  \n- **Cardiovascular:** No chest pain, no palpitations.  \n- **Gastrointestinal:** Occasional GI upset with Metformin, no nausea or vomiting.  \n- **Genitourinary:** Regular menstrual cycles.  \n- **Musculoskeletal:** No joint pain or swelling.  \n- **Dermatological:** No skin changes, no wounds.\n\n**Past Medical History:**  \n- Type 2 Diabetes Mellitus  \n- Hypertension  \n- Hyperlipidemia\n\n**Medications:**  \n- Metformin 1000mg twice daily  \n- Lisinopril 20mg daily  \n- Atorvastatin 20mg daily\n\n**Allergies:**  \nNo known drug allergies.\n\n**Social History:**  \nJane is an elementary school teacher with a mostly sedentary lifestyle. She engages in minimal physical activity and consumes sugar-sweetened beverages daily. She is not currently planning a pregnancy.\n\n**Physical Examination:**  \n- **Vital Signs:** BP 128/78 mmHg, HR 78 bpm, Temperature 98.6\u00b0F, Weight 185 lbs, BMI 32.4  \n- **General:** Alert, obese, pleasant.  \n- **Cardiovascular:** Regular rate and rhythm, no murmurs, peripheral pulses 2+ dorsalis pedis and posterior tibial bilaterally.  \n- **Respiratory:** Clear to auscultation bilaterally.  \n- **Extremities:** Monofilament test shows protective sensation intact bilaterally. Skin intact without wounds or calluses, no edema, pedal pulses palpable.  \n- **Feet:** No deformities, nails trimmed, no fungal infection.\n\n**Assessment and Plan:**  \n1. **Type 2 Diabetes Mellitus, uncontrolled (ICD-10: E11.65)**\n   - Add Semaglutide 0.25mg subcutaneous weekly, increase to 0.5mg after 4 weeks.\n   - Continue Metformin 1000mg twice daily.\n   - Order HbA1c in 3 months.\n   - Referral to diabetes educator for nutrition counseling.\n   - Discussed glucose targets and HbA1c goals.\n   \n2. **Obesity (ICD-10: E66.9)**\n   - Lifestyle counseling: Eliminate sugar-sweetened beverages, portion control, increase physical activity to 150 min/week.\n   - Weight loss goal: 5-10% body weight over 6 months.\n\n3. **Essential Hypertension, controlled (ICD-10: I10)**\n   - Continue Lisinopril 20mg daily.\n\n4. **Hyperlipidemia (ICD-10: E78.5)**\n   - Continue Atorvastatin 20mg daily.\n\n5. **Neuropathy symptoms**  \n   - Monitor and reassess in follow-up.\n\n6. **Preventive Care**\n   - Referral to ophthalmology for annual dilated eye exam.\n   - Order annual kidney function tests.\n   - Ensure flu vaccine, check pneumococcal status.\n   - Discussed need for reliable contraception.\n\n**Time Spent:**  \n25 minutes spent with the patient, including extensive medication counseling and lifestyle education.\n\n**Billing Level:**  \n99214 (Established patient, moderate to high complexity due to uncontrolled chronic disease).\n\n**Medical Decision Making:**  \nUncontrolled diabetes with HbA1c above target necessitating addition of GLP-1 agonist for glucose control and weight management. Cardiovascular risk addressed with current medication regimen. Screenings for complications current except for ophthalmologic referral. Addressed lifestyle modifications and barriers. Educated on Semaglutide use and side effects. Return in 6 weeks to assess medication tolerance and response.",
  "demographics": {
    "age": 35,
    "gender": "F",
    "occupation": "elementary teacher",
    "name": "Jane Doe"
  },
  "generated_at": "2026-02-14T01:56:20.070867",
  "ground_truth_scores": {
    "completeness": 92,
    "accuracy": 95,
    "compliance": 90,
    "risk": 88,
    "clarity": 93
  }
}